When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Area of Science:

• Oncology
• Immunotherapy
• Genomics

Background:

• Advanced non-small cell lung cancer (NSCLC) treatment has been revolutionized by targeted therapies and immune checkpoint inhibitors (ICI).
• Patients with oncogenic drivers have often been excluded from ICI clinical trials, leaving their outcomes with immunotherapy poorly understood.
• The optimal role of immunotherapy in NSCLC patients with oncogenic addiction remains undefined.

Purpose of the Study:

• To review the current understanding of immunotherapy use in advanced NSCLC patients with oncogenic drivers.
• To propose evidence-based strategies for integrating immunotherapy into treatment algorithms for this specific population.
• To highlight the need for further research and biomarker identification.

Main Methods:

• Review of available clinical data and trial outcomes.
• Expert opinion and synthesis of current evidence.
• Formulation of treatment recommendations based on existing knowledge.

Main Results:

• Targeted therapy is the primary treatment for oncogenic-addicted NSCLC.
• Immunotherapy as a single agent is recommended only after other validated treatments are exhausted.
• Combinations of immunotherapy with targeted or chemotherapy agents show potential but require careful management of toxicity and sequencing.

Conclusions:

• Treatment strategies for advanced NSCLC with oncogenic drivers should prioritize targeted therapies.
• Future research should focus on identifying biomarkers to guide the optimal sequencing and combination of immunotherapy with other treatment modalities.
• Careful consideration of toxicity and treatment sequencing is crucial when combining immunotherapies with targeted or chemotherapy agents.